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Abstract  
Elevated LDL concentration in mid-life increases the risk of developing Alzheimer’s disease (AD) in 
later life. Increased oxidative modification (oxLDL) and nitration is observed during dementia and 
hypercholesterolemia.  
We investigated the hypothesis that statin intervention in mid-life mitigates the inflammatory 
effects of oxLDL on the microvasculature. Human microvascular endothelial cells (HMVEC) were 
maintained on transwells to mimic the microvasculature and exposed to patient and control LDL. 
Blood was obtained from statin-naïve, normo- and hyperlipidaemic subjects, AD with vascular 
dementia (AD-plus) and AD subjects (n=10/group) at baseline. Only hyperlipidaemic subjects with 
normal cognitive function received 40mg simvastatin intervention/day for three months.  Blood was 
re-analysed from normo- and hyper-lipidaemic subjects after three months.  
LDL isolated from statin-naïve hyperlipidaemic, AD and AD-plus subjects was more oxidised (agarose 
gel electrophoretic mobility, protein carbonyl content and 8-isoprostane F2ɲ) compared to control 
subjects. Statin intervention decreased protein carbonyls (2.5±0.4 Vs 3.95±0.2nmol/mg; P<0.001) 
and 8-isoprostane F2ɲ (30.4±4.0 pg/ml Vs 43.5±8.42 pg/ml; P<0.05). HMVEC treatment with LDL-
lipids from hyperlipidaemic, AD and AD-plus subjects impaired endothelial tight junction expression 
and decreased total glutathione levels (AD; 18.61±1.3, AD-plus; 16.5±0.7nmol/mg protein) 
compared to untreated cells (23.8±1.2 vs nmol/mg protein). Basolateral IL-6 secretion was increased 
by LDL-lipids from hyperlipidaemic (78.4±1.9 pg/ml), AD (63.2±5.9 pg/ml) and AD-plus (80.8±0.9 
pg/ml) groups compared to healthy subject lipids (18.6±3.6 pg/ml). LDL-Lipids isolated after statin 
intervention did not affect endothelial function.  
In summary, LDL-lipids from hypercholesterolaemic, AD and AD-plus patients are inflammatory to 
HMVEC. In vivo intervention with statins reduces the damaging effects of LDL-lipids on HMVEC.  
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Introduction 
In the adult brain, primary cholesterol synthesis occurs in astrocytes and to a lesser extent in 
neurons [1]. Cholesterol is transported within the brain by local lipoproteins.  Brain cholesterol 
metabolism is discrete from metabolism in peripheral tissues and the central nervous system (CNS), 
and plasma cholesterol/lipoprotein compartments are strictly segregated by the blood brain barrier 
(BBB).  
The BBB is created by the tight junctions between the endothelial cells of brain microvascular tissue 
assisted by the astrocyte foot processes surrounding the capillary endothelial cells [2, 3]. Transfer 
across the BBB to the CNS is achieved via ATP-dependent transporters, facilitated diffusion, 
transmembrane diffusion, and leakage through extracellular pathways.   
There is no evidence that normal lipoprotein cholesterol (C) (e.g. high density lipoprotein-C; HDL-C 
and low density lipoprotein-C; LDL-C) originating in the plasma compartment routinely crosses the 
BBB to be transported into the CNS [4].  In support of this, knockout of the LDL receptor gene in mice 
and rabbits or disruption of peripheral SR-BI or ABCA1 in mice changes neither the cholesterol 
synthesis rate nor the cholesterol concentration in the brain [5, 6].  Taken together, these data are in 
agreement with the view that plasma cholesterol is not transported to the brain because plasma 
lipoproteins do not cross the BBB. Nevertheless, prospective studies have shown a reduced risk for 
AD in users of cholesterol-lowering statin drugs [7]. Many previous studies demonstrated the 
beneficial effects of statins on endothelial dysfunction and chronic inflammation [8, 9]. In addition, 
an association between previous statin use and reduced neurofibrillary tangle burden post-mortem 
has also been reported [10, 11]. In the TgCRND8 mouse model of AD, a reduction in ɴ amyloid 
accumulation was been observed in the brain after treatment pravastatin, a non-hydrophilic, non-
blood brain barrier (BBB)-permeant statin [12], supporting the hypothesis that peripheral cholesterol 
metabolism is important to brain pathology.  
Hypercholesterolaemia is an important contributor to oxidative stress [13], a condition of an 
imbalance between oxygen free radical production and removal by antioxidant enzymes and 
micronutrients. If radical production exceeds that which can be controlled by antioxidants, 
irreversible damage to proteins, lipids and DNA occurs. Evidence for oxidation and nitration of 
proteins to form carbonyl groups and 3-nitrotyrosine is frequent in plasma from both 
hypercholesterolaemic and dementia patients [14, 15]. Similarly, free radical-oxidised lipids (e.g. 
isoprostanes, lipid hydroperoxides) are more prevalent in plasma from AD and 
hypercholesterolaemic subjects compared to controls [16]. Together, these studies implicate 
systemic lipid/protein oxidation as common a common feature of AD and hypercholesterolaemia. 
Whilst the beneficial effects of statins against cardiovascular disease in the latter group have been 
attributed to reduction in cholesterol, recent studies suggest that benefit is due to oxidised LDL 
removal [17]. Indeed, clinical trials showing protective effects of statins against AD do not show that 
a reduction in plasma cholesterol correlates with reduced risk for AD, indicating that an alternative 
mechanism for the beneficial effects of statins may be present [18]. It is not known whether removal 
of oxidised LDL accounts for the protective effects of statin-usage in mid-life against the later AD 
development. 
Therefore, we have examined the hypothesis that systemic oxidised LDL affects the function of 
microvascular endothelial cells to secrete inflammatory mediators into the brain compartment 
predisposing to AD and that statin intervention renders LDL less inflammatory. We have undertaken 
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qualitative and quantitative analysis of lipid oxidation products in LDL isolated from mid-life subjects 
with elevated plasma cholesterol, investigated whether statin intervention in hypercholesterolaemic 
subjects can prevent modifications to LDL in vivo and whether any protection of LDL oxidation 
restores normal microvascular endothelial cell function.  
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Materials and Methods 
Plasma sample preparation 
Twenty mid-life male adults (40-60 years old, mean age 46.9 years) were recruited from general 
medical practices in the Birmingham area with (total cholesterol >6.5mM measured) and without 
hypercholesterolaemia. All hypercholesterolaemic subjects were unresponsive to lifestyle change, 
were statin-naïve and were not taking any disease modifying anti-inflammatory medication or 
nutritional supplements. All subjects were healthy by careful clinical history and examination, and 
scored at least 27 on the mini-mental state examination. The research has been carried out in 
accordance with the Declaration of Helsinki (2008)   of the World Medical Association and ethical 
approval was obtained from the Birmingham and Black Country Local Research Ethics Committee 
(REC 09/H1202/87). Participants provided informed written consent. 
 
After an overnight fast, 5mL whole blood was drawn from the antecubital vein of each participant 
and collected into ethylenediaminetetraacetic acid (EDTA) coated tubes (Greiner Bio-One Ltd, UK) 
between 8:00 and 10:30 am as a baseline measure. All ten statin-naïve, hypercholesterolaemic 
subjects were started on simvastatin intervention (40mg/day) as a revision to their routine 
management after lifestyle changes had failed to reduce blood cholesterol, whereas 
normolipidaemic subjects maintained habitual diets and lifestyles without intervention. According to 
NICE guidelines (guidance.nice.org.uk/cg181) patients were recruited after 3 months to a second 
blood sampling. All ten hypercholesterolaemic patients completed the intervention for the study 
duration of 3 months. AD subjects were recruited from the Unit of Cognitive Frailty, Neurology 
Outpatient Clinic, Cologne, Germany, after diagnosis of AD using NINCDS–ADRDA criteria either in 
the presence of vascular comorbidities and risk factors (high cholesterol, hypertension, stroke, type 
2 diabetes mellitus, myocardial infarction and heart arrhythmia; AD-Plus group) or without 
cardiovascular comorbidities and risk factors (AD group) [19]. Three patients in the AD group were 
diagnosed with hypertension alone. After an overnight fast, 5mL whole blood was drawn from the 
antecubital vein of each participant and collected into ethylenediaminetetraacetic acid (EDTA). 
Informed consent was obtained from the patients or their care givers according to severity of 
disease and the study was approved by the local ethics committee. Blood plasma was prepared by 
centrifugation (200 g, 30 min) and stored immediately at -800C prior to analysis and extract LDL.  
 
Isolation, modification, characterisation of LDL and LDL-lipids  
All blood samples were obtained using LDL was isolated, modified and characterised as previously 
[20]. LDL protein concentration was analysed by Bicinchoninic acid assay (Sigma Aldrich, UK). In 
addition, LDL lipid content was analysed by Amplex® Red cholesterol assay kit (Life Technologies, UK) 
and phospholipid assay. The degree of lipid oxidation of LDL and oxLDL was determined as 8-
isoprostane F2ɲ levels (15.5±1 pg/mg of LDL and 26±2.5 pg/mg of oxLDL) by EIA method according 
to manufacturer’s instructions (Cayman Chemicals). LDL-lipids (LDL-L) or oxLDL-lipids (oxLDL-L) were 
extracted from LDL using the Folch method by addition of 160 ʅl of ice-cold methanol (containing 50 
ʅg/ml BHT) followed by the addition of 320 ʅl of ice-cold chloroform and incubation for 20 min on 
ice with occasional vortex mixing. High-purity water (150 ʅl) was added and the sample kept on ice 
for an additional 10 min with occasional mixing. The sample was centrifuged for 5 min at 200 g and 
the upper (aqueous) phase was removed and re extracted by addition of 250 ʅl of ice-cold 
chloroform: methanol (2:1,v/v) as above. The upper phase was discarded and both organic phases 
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were combined, dried under nitrogen gas, and kept at -800 C until further use. Extracted lipids for 
cell culture experiments were conjugated to fatty acid-free bovine serum albumin (BSA) in serum-
free RPMI 1640 [25]. 
Phospholipid assay 
Total phospholipid content in HMVEC cell lysates were analysed as described previously with some 
modifications [21]. A phospholipid standard curve (0.005- 0.05 mg/mlegg yolk lecithin) was 
prepared by diluting 0.1 mg/ml stock solution in chloroform in glass vials. 1ml of 0.1N ammonium 
ferrothiocyanate (2.7 g ferric chloride hexahydrate ( FeC13.6H20) and 3.04 g ammonium thiocyanate 
(NH4SCN) in deionized distilled water and made up to 100ml) was added to 1ml of lipid standards or 
sample and vortexed for 1 min. The layers were allowed to separate for 5min before removing 
chloroform layer into a new glass tube. Samples and standards were read in spectrophotometer at 
488nm using a quartz cuvette.   
Agarose gel electrophoresis 
Lipoprotein was assessed by 1% agarose gel electrophoresis in barbital buffer as described 
previously [22]. Briefly, bromophenol blue in glycerol (50%; 4 ʅl) was added to LDL samples (20 ʅg) 
before electrophoresis in barbital buffer (sodium barbital 10.6 g/L, pH 8.6) for 2 h at 55 V. Gels were 
stained with Coomassie brilliant blue to visualise proteins for around 45 min. The gel was destained 
(40% methanol, 10% acetic acid, 50% water), for 30 min, prior to exchange for fresh destain and 
then left overnight. Rf values were calculated for each sample as the distance the sample moved 
from origin (mm) divided by the distance travelled by the dye front (mm). 
 
Microvascular endothelial model 
Human microvascular endothelial cells (HMVEC, Invitrogen, Life technologies, UK) were seeded 
(3×105/ml) onto 24-well polycarbonate inserts and cultured for 7days. LDL-L or oxLDL-L (0.4-8 ђg) or 
control/patient LDL-L (4ђg) was added onto endothelial barrier for 24 hours before measuring the 
change in barrier permeability after treatment with 200ђl of 1mg/ml FITC-dextran apically for 24 
hours. The basolateral and apical media was collected, the apical surface washed twice, the washes 
collected and combined with the apical media collected. Fluorescence of the media was read at the 
following wavelengths; excitation 488nm and emission wavelength 520nm using a Spectra Max 
Gemini XS fluorimeter (Molecular Devices). The percentage fluorescence in the basolateral 
compartment was calculated as a measure of cell permeability.  
 
ELISA  
Following the cell treatments with lipids, cell culture media was collected and cells were pelleted by 
centrifugation (200g, 10mins), cell free media containing secreted cytokines was stored at -20OC 
until analysis for interleukin (IL)-6 and tumour necrosis factor (TNF)ɲ by ELISA (Peprotech, UK). 
 
Cell viability assay 
Cell viability was measured using the Cell Titer-Blue® viability assay. After incubation with 100ђl of 
Cell Titer-Blue®, supernatants from Transwell® inserts were removed to a 96 well plate and 
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fluorescence measured at excitation (Ex) 560nm emission (Em) 590nm using a Spectra Max Gemini 
XS fluorimeter (Molecular Devices).   
 
Zona occludens-1 (ZO-1) staining 
HMVEC were seeded onto transwell inserts and after 7 days cells were fixed with 100% methanol 
(pre-cooled) prior to permeabilisation with 0.1% (v/v) Triton X-100. Cells were then blocked with 
100ђl 1% (v/v) normal goat serum before incubating with mouse monoclonal anti-ZO-1 diluted 1:250 
in 1% bovine serum albumin (BSA) overnight at 4°C. Cells were then stained with goat anti-mouse 
fluorescein isothiocyanate (FITC)-conjugated secondary antibody diluted 1:100 in 1% BSA and 
mounted with hard set mounting medium containing 4',6-diamidino-2-phenylindole (DAPI) for 48 
hours at 4°C in the dark. Images were visualized using a Zeiss LSM 510 META confocal laser-scanning 
microscope (Leica Microsystems, Milton Keynes, UK) with the x63 oil objective, the green filter cube 
(495nm) and the blue filter cube (365nm) for visualisation. Images were analysed using the LAS AD 
Lite software (Leica Microsystems, Milton Keynes, UK). 
 
 
Glutathione (GSH) assay 
HMVEC GSH levels were measured by GSH- Glo assay (Promega). 
 
Lipid peroxidation analysis  
Plasma 8-isoprostane F2ɲ was measured by ELISA (Cayman Chemicals). This kit provided Inter-assay 
variation (%CV) of 16.6 and intra assay variation (%CV) of 16.2.  A lower limit of detection was 
20pg/ml. 
 
Statistical analysis 
Statistical significance was tested by using ANOVA with Tukey’s post-test, student’s T test or 
Wilcoxon’s matched paired T test using Prism 6 (Graphpad). Unless specified all data are presented 
as the mean ± SEM of at least three independent experiments, each performed in triplicate. 
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Results 
 
LDL and oxLDL-lipids increase microvascular endothelial permeability in vitro 
Previously we have shown that LDL and its lipids are more oxidised in dementia, therefore we 
examined the effects of LDL and LDL-lipids that had been isolated from patients with 
hypercholesterolemia or dementia and their respective controls directly on HMVEC.  
HMVEC were cultured on transwells until a barrier was formed with ZO-1 expression localised to 
membrane junctions at day 7. Monolayers were subsequently exposed to control LDL from healthy 
donors with and without oxidation for 24 hours. LDL and oxLDL treatments (ч 4ђg) did not affect 
endothelial function as measured by permeability to FITC dextran or cell viability (supplementary 
figure 1). To further explore whether the loss of endothelial function after 8ђg of oxLDL is due to 
protein or lipid fractions, LDL was sub-fractionated. LDL-lipids and oxLDL-lipids increased barrier 
permeability significantly in a concentration dependent manner (Figure 1A), while LDL-protein had 
no significant effect (supplementary figure 2). Lipids fractionated from oxLDL and LDL caused a 
significant inhibition of metabolic activity after addition of >4ђg and 8ђg respectively (Figure 1B). 
Despite evidence of cell stress, measured as metabolic inhibition, there was no significant release of 
lactate dehydrogenase (LDH) when treated with 4ђg LDL- or oxLDL-lipids (supplementary figure 3). 
Addition of LDL or lipids isolated from 4 ђg LDL led to a three-fold increase in cellular cholesterol 
concentration (supplementary figure 4). 
To determine whether the disruption of tight junction-associated protein was linked to loss of 
barrier integrity, we immuno-stained HMVEC cells for ZO-1 before and after LDL-lipid treatments. 
After treatment with a non-toxic but barrier-disturbing concentration of LDL-lipids (4ђg), ZO-1 
staining was diffuse (Figure 1D) and ZO-1 was not visible on the margins of the cytoplasmic 
membrane surface; nevertheless, membranes appeared intact. Staining after LDL-lipid addition was 
unlike the ZO-1 staining pattern that was observed for untreated, control HMVEC. 
 
LDL- and oxLDL-lipids increase NF-kB-dependent basolateral secretion of TNF-ɲ and IL-6  
To explore whether LDL, oxLDL and sub fractions of LDL can trigger endothelial inflammatory 
responses, HMVEC were cultured on transwells until a tight barrier was formed, then exposed 
apically to LDL- and oxLDL-L. Directional secretion of pro-inflammatory mediators was analysed in 
both apical and basolateral compartments. oxLDL-L lipids significantly increased both apical and 
basolateral secretion of TNF-ɲ (Figure 2A) and IL-6 (Figure 2B) compared to LDL-L treated cells.  
To determine whether the increase in cytokine secretion was due to activation of NFkB, the 
inhibitory peptide SN50 was included when HMVEC were exposed to lipid fractions of LDL and 
oxLDL. SN50 significantly inhibited IL-6 (Figure 2C) and TNF-ɲ (Figure 2D) production, without 
interfering with cell viability (supplementary figure 5) confirming the importance of NFkB activation 
in the effects of LDL and oxLDL-lipids on HMVEC.  
To understand whether the increase in cytokine secretion that is elicited by LDL-L and oxLDL-L in an 
NF-kB-dependent manner is associated with an altered redox state, we examined intracellular GSH 
in HMVEC after over 2 hours of lipid treatments.  LDL-L (oxidised and control) significantly depleted 
cellular GSH concentration (Figure 2E) and this mirrored the patterns of cytokine secretion. 
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Effect of hypercholesterolemia and statin intervention on LDL oxidation in midlife  
Statin intervention in mid-life is reported to reduce incidence of dementia in later life, therefore we 
have undertaken a qualitative and quantitative analysis of lipid oxidation products in LDL from 
hypercholesterolaemic patients compared to age-matched controls whose cholesterol levels are 
within the normal range; their baseline characteristics are reported in Table 1.  
LDL isolated from statin-naïve hypercholesterolaemic subjects showed a trend for higher 
electrophoretic mobility at baseline by agarose gel electrophoresis (Rf; 0.53±0.06) compared to 
control subjects (Rf; 0.46±0.05), Figure 3A. To investigate levels of circulating protein and lipid 
oxidation in the patients and controls, plasma was analysed for protein carbonyls and 8-isoprostane 
F2ɲ (Figure 3B and C). Statin-naïve hyperlipidaemic subjects had higher plasma carbonyls (3.95±0.2 
nmol/mg; P<0.001) and 8-isoprostane F2ɲ (43.5±8.42 pg/ml; P<0.01) compared to control subjects 
(2.65±0.15 nmol/mg and 24.2±5.37 pg/ml respectively). Statin treatment for 3 months significantly 
decreased blood cholesterol levels (from 6.72 ± 0.78mM to 4.63 ±0.31 mM; P<0.001), plasma 
carbonyl (2.5±0.4; P<0.001) and 8-isoprostane F2ɲ levels (30.4±4.0 nmol/mg; P<0.05).  
 
Effect of LDL from hypercholesterolemic patients pre- and post-statin intervention on endothelial 
function. 
Compared to HMVEC treatment with the LDL-lipids (4ʅg of LDL) from normolipidaemic subjects, LDL-
lipids from hyperlipidaemic subjects increased endothelial  permeability as observed by FITC dextran 
permeability (Figure 4A; P<0.05) and immunohistochemistry for tight junctions was decreased 
(Figure 4B and C; P<0.001). At the baseline, the percentage of endothelial cells with tight junctions 
was significantly decreased upon patient LDL-lipids treatment. After 3 months of statin intervention, 
LDL-lipids did not change the percentage of cells expressing junctional ZO-1 compared to control 
LDL-lipids.  At the baseline, LDL-lipids from patients decreased GSH (15.94±1.0 nmol/mg v 12.2±0.6 
nmol/mg; P<0.01 untreated cells 22.75±1.2 nmol/mg of protein; N=10/group), Figure 4D. After 3 
months treatment with statins, there was no difference between the effects of LDL isolated from 
either patients or controls on HMVEC function. 
 
LDL-lipids from patients with Alzheimer’s disease act as inflammatory triggers in microvascular 
endothelial cells 
To explore whether LDL-lipids from patients with dementia are more oxidised than controls and to 
investigate their inflammatory effects, the endothelial model was treated with 4ђg of LDL-lipids from 
each patient individually from the three groups, AD, AD-Plus and control subjects. Although the total 
cholesterol and LDL cholesterol levels between subject groups were not different (Table 2), AD-Plus 
patients had higher plasma 8-isoprostane F2ɲ levels (Figure 5A; 39.93±3 pg/ml) compared to the 
healthy control group (30.08±1.8 pg/ml). There was an increase of endothelial permeability with AD 
and AD-Plus LDL-lipid treatments and intracellular GSH levels were decreased (23.8±1.2 vs 16.5±0.7 
nmol/mg protein). AD-Plus LDL-lipids were also more inflammatory as measured by basolateral 
secretion of IL-6 (80.8±1 Vs 18.6±3.6pg/ml). 
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Discussion  
In this study we show that the activation of microvascular endothelial cells with LDL-lipids increased 
the secretion of inflammatory mediators TNF-ɲ, IL-6 and decreased the membrane localisation of 
the tight junction protein, ZO-1. LDL-lipids isolated from patients with hypercholesterolaemia were 
more oxidised and inflammatory towards endothelial cells than those from healthy age-matched 
subjects. Similarly, LDL-lipids from AD-Plus patients were found to contain higher level of lipid 
peroxidation and promoted more inflammatory IL-6 secretion from endothelial cells compared to 
controls. After, simvastatin intervention for three months in hypercholesterolaemia patients, LDL-
lipid oxidation was decreased and the inflammatory effects of isolated LDL on endothelial cells were 
reduced. These findings support the hypothesis that elevated cholesterol in mid-life increases the 
concentrations of oxidised LDL molecules which in turn can elicit a directional inflammatory 
response and results in tissue inflammation. It has been described previously that inflammatory 
cytokines secreted by endothelial cells can exert an autocrine disruption of endothelial tight junction 
integrity [23]. During neurodegenerative conditions the barrier property of brain microvascular 
endothelial cells is thought to be damaged by disruption of junctional proteins resulting in barrier 
leakage [24]. Moreover, cerebral endothelium disruption and white matter lesions typical of 
dementia are observed more frequently in diabetes and hypercholesterolaemic patients compared 
to healthy controls [25].  
The BBB consists of microvascular endothelial cells that are adjoined by specific protein tight 
junctions (e.g. occludins, ZO-1, ZO-2, ZO-3, claudins and cingulins) with their basement membrane, 
underlying brain pericytes and astroglial foot processes [25]. In healthy brains these layers display 
specific and tightly regulated transport mechanisms between the blood and ventricular 
cerebrospinal fluid [25]. Although normal ageing increases BBB permeability [25], oxLDL promotes 
endothelial activation including increased monocyte adhesion to the vascular wall and induction of 
NFʃB. There is controversy over whether ageing alone associates with increased BBB permeability; 
Pelegri et al [26] have reported an early increase in permeability in the senescence-accelerated 
mouse model SAMP-8 at 12 months which is not present in control animals and is suggested to 
underlie deficits in learning and memory. SAMP-8 mice are also characterised by early loss of 
antioxidant enzymes i.e. of altered control of the scavenging of oxidative species [27].  
In a model of localised excitotoxicity-induced neurodegeneration, BBB breakdown in itself was not 
sufficient to elicit cell death; a subsequent peroxynitrite-mediated event was required [28]. 
Peroxynitrite is lipophilic and can cross membranes via diffusion in the absence of a transporter. 
While the BBB requires the presence of carrier/proteins and transporters for rapid molecular 
transport of nutrients e.g. fatty acids, direct uptake of lipid hydroperoxides proceeds at an eight 
times faster rate than diffusion-controlled uptake of parent lipids [29]. Thus, clear pathways exist for 
transport of reactive species and modified lipids from the periphery to the CNS where they are 
neurotoxic to hippocampal neurones. 
To better understand whether oxidised LDL was disruptive to an endothelial barrier, in vitro 
minimally modified LDL was prepared [19] from a pool of healthy subjects. This approach was taken 
to represent range of oxidation present in LDL. CuSO4 based method to prepare minimally oxidised 
LDL is well characterised in literature showing similar levels of oxidation to those seen in patients 
with vascular disease [24].  In line with literature, oxLDL displayed significantly higher inflammatory 
activity towards endothelial cells than freshly prepared LDL from control subjects [30]. Prior to 
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ascribing physiological significance to these findings, oxLDL lipid effects on the BBB should be tested 
in vivo.  
After the LDL was sub-fractionated, it was the lipid but not the protein components that mediated 
cell stress. We did not measure any quantitative difference in the uptake of lipids whether they were 
delivered by LDL or bound to albumin after 24 hours. This does not preclude a possible difference in 
rate of delivery. OxLDL-lipids elicited the greatest loss of GSH which has been reported by others to 
lead to an increase in NFkB activation in endothelial cells [31].   In turn, NFʃB can regulate multiple 
proinflammatory target genes (21). NFkB activation and downstream expression of cytokines is 
controlled at least in part by the intracellular redox state. A shift towards a more oxidised 
environment increases phosphatase oxidation and inactivation, thus propagating inhibitor kappa 
kinase cascade activity and IKK dissociation from NFkB (23).  
Oxidised LDL are known to cause barrier disruption in mice which has been attributed to a decrease 
in the expression of actin-depolymerizing factor (ADF) [32]. Others showed that overexpression of 
ADF attenuated ox-LDL-induced disruption of endothelial barrier marked by restoration of trans-
endothelial electrical resistance, permeability of Evans Blue and expression of tight junction-
associated proteins including ZO-1 and occludin, and blocked ox-LDL-induced oxidative stress (22). 
Differential expression of inflammatory and actin remodelling proteins by endothelial cells has also 
been shown after exposure to serum from patients with chronic kidney disease [33] suggesting a 
common association between endothelial cell response to plasma components.   
Consistent with previous reports, we observed that LDL is more oxidised in hypercholesterolaemia 
patients [17]. Of note, plasma protein carbonyl and isoprostane concentrations described previously 
in AD-Plus patients [14, 20] were not different to those reported here for hypercholesterolaemic 
patients. Importantly, after patients were treated with statins their LDL oxidation measured as both 
protein and lipid oxidation was no different from healthy control subjects. However, we 
acknowledge the fact that this study involved small cohort size (n=20) and this limits the statistical 
power. 
The present data show for the first time that lipids from LDL of untreated hypercholesterolaemic 
patients trigger the loss of microvascular barrier integrity. Moreover, the increased lipid toxicity in 
LDL from hypercholesterolaemic patients compared to control subject LDL towards microvascular 
endothelial cells was prevented after intervention with simvastatin for 3 months. In a similar 
manner, when LDL was examined from patients with AD and AD-Plus, isoprostane concentrations 
were higher as previously described [14]. Moreover, their lipids were more proinflammatory to 
endothelial cells promoting a significant increase in basolateral IL-6 directional secretion associated 
with loss of GSH. When considered alongside the importance of BBB integrity for brain health, these 
observations suggest an explanation for the observed reduction in dementia incidence for those 
receiving  statins, independently of a reduction in plasma cholesterol and which may be attributed 
to statin effects on lipid oxidation [34]. 
These data support the hypothesis that statins exert a protective effect against in microvascular 
damage by modulating LDL by a mechanism that may not only be dependent on reducing cholesterol 
concentration and may be due to their capacity to prevent LDL oxidation. This may account for the 
protective effects of statin-usage in mid-life against the later dementia development and offers a 
rationale for managing patients with elevated oxLDL and mild or subjective cognitive impairment 
using statins. 
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In conclusion, this study demonstrated that LDL-lipids from AD and AD-Plus patients are more 
damaging to endothelial barrier properties and increase release of inflammatory cytokines. These 
data support the hypothesis that in vivo intervention with statins modifies LDL lipid oxidation and 
exert a protective effect against in microvascular damage in a manner that is independent of 
cholesterol concentration. This may account for the protective effects of statin-usage in mid-life 
against the later development of AD. 
Clinical Perspectives  
x We have explored why patients who have been prescribed lipid-lowering drugs in mid-life 
are at lower risk for dementia. We identified a novel anti-inflammatory effect for statins in 
patients with hypercholesterolaemia, by preventing LDL-lipid oxidation. 
x The inflammatory and oxidising effects of LDL fractions towards microvascular endothelial 
cells (measured as directional cytokine secretion and cellular glutathione) were greatest for 
oxLDL-lipids and then LDL-lipids with oxLDL-protein being the least inflammatory. Moreover, 
in common with adults with hypercholesterolemia, LDL from AD-Plus and AD patients was 
more oxidised, elicited more endothelial glutathione depletion, more IL-6 secretion and 
impaired endothelial tight junctions. 
x Thus, the mechanisms triggering LDL oxidation and the ability of oxidised LDL to endothelial 
dysfunction could be targeted by statins to reduce the risk for vascular involvement and 
dementia development. 
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Summary statement 
We have established a novel role of statins for mid-life adults with high blood cholesterol in depleting 
inflammation and oxidation of fats in the “bad” cholesterol particle, LDL. Oxidised LDL-fats were also higher in the 
blood of patients with dementia and caused inflammatory damage to cells that line blood vessels.   
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Table 1: Demographics of healthy control and hypercholesterolaemic patient populations. The 
healthy control subjects continued a normal lifestyle and hypercholesterolaemic patients receievd 
simvastatin (40mg/d) for 3 months. 
  
 Baseline 3 months follow up 
 Control 
(n=10) 
Hyper-
cholesterol
aemic  
(n=10) 
p Control 
(n=10) 
Hyper-
cholester
olaemic  
(n=10) 
p 
Weight (Kg) 62 ± 2.47 63.8 ± 2.69 >0.05 61±2.3 64±2.7 >0.05 
BMI Kg/m2 24.88 ± 0.74 26.35 ± 1.1 >0.05 24.7±0.68 26.3±1.2 >0.05 
Cholesterol 
(mM) 
4.08 ± 0.18 6.72 ± 0.78 <0.001 3.8±0.13 4.63±0.31 >0.05 
Age (years) 46.4 ± 1.7 47.4 ± 1.7 >0.05 46.4 ± 1.7 47.4 ± 1.7 >0.05 
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  Control (n=10) AD (n=10) AD-Plus 
(n=10) 
p 
Age (years) 73 ± 2.5 81 ± 1.4 80 ± 1.7 >0.05 
BMI Kg/m
2
 
23.7 ± 0.34 24.1 ±  0.69 25.8 ± 0.36 >0.05 
Total Cholesterol (mmol/L) 5.67 ± 0.17 5.24 ± 0.32 4.9 ± 0.2 >0.05 
LDL Cholesterol (mg/dL) 121.5 ± 7.6 113.2 ± 11.1 108.3 ± 10.0 >0.05 
Table 2:  Demographics of mid-life adult volunteers   
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Figure 1: The effect of LDL, oxLDL-lipids on endothelial barrier permeability. HMVEC cells 
(1×105cells) were seeded in transwell inserts for 2 weeks before lipid treatments. HMVEC were 
treated with increasing concentrations of LDL-lipids and oxLDL-lipids for 24 hours. Barrier tightness 
was measured by FITC dextran permeability (A). Cell metabolic activity was measured by CellTiter-
Blue® assay (B).  Tight junction protein ZO-1 is stained in green, nuclei stained in blue DAPI stain in 
HMVEC cells before (C) and after (D) treating with LDL-lipids (from 4ʅg LDL). ** P<0.01, *** P<0.001, 
n=3 independent experiments. 
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Figure 2: The effect of LDL-L and oxLDL-L on endothelial barrier inflammation. HMVEC cells (1×105 
cells) were seeded in transwell inserts for 2 weeks before lipid treatments. HMVEC were treated 
with increasing concentrations of LDL-lipids for 24 hours (A&B) or LDL (4ђg; C&D). Cells were co-
C o
n t
ro
l
L D
L
L D
L +
S N
5 0
o x
L D
L
o x
L D
L +
S N
5 0
L D
L -
L i
p i
d s
L D
L -
L i
p i
d s
+ S
N 5
0
o x
L D
L -
L i
p i
d s
o x
L D
L -
L i
p i
d s
+ S
N 5
0
0
2 0
4 0
6 0
8 0
1 0 0
B
a
so
la
te
ra
l I
L
-6
 p
g
/m
l
***
****
****
C
o n
tro
l
L D
L
LD
L +
S N
5 0
o x
LD
L
o x
LD
L +
S N
5 0
LD
L -
L i
p i
d s
L D
L -
L i
p i
d s
+ S
N
5 0
o x
LD
L -
lip
id
s
o x
LD
L -
L i
p i
d s
+ S
N
5 0
0
2 0
4 0
6 0
8 0
B
a
so
la
te
ra
l T
N
F
- D
 p
g
/m
l
* * *
* * *
* * *
C o
n t
ro
l
0 .
8
1 .
6 4 8
0
1 0
2 0
3 0
4 0
L D L -L ip id s  (P g  L D L )
G
S
H
 (
n
m
o
l/
m
g
 p
ro
te
in
)
* *
E
L D L -L
o x L D L -L
* * * * *
* * * *
20 
 
incubated with 20ђM SN-50 before measuring IL-6 (A&C) and TNF-ɲ (B&D) in both apical and 
basolateral media by ELISA. The level of cellular GSH (E) was determined by the GSH-glo assay. Data 
are expressed as mean + SEM, *P<0.05, ** P<0.01, ***P<0.001, ****P<0.0001, n=3 independent 
experiments.  
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A. 
 
   
Figure 3: LDL from statin-naïve hypercholesterolaemic patients is more oxidised than LDL from 
healthy controls and statin treatments reduced LDL oxidation. Following density gradient 
ultracentrifugation, LDL electronegativity was examined by agarose gel electrophoresis (A). Protein 
carbonyls (B) and 8-isoprostane F2ɲ (c) were determined in plasmas from 10 controls and 10 
patients analysed in triplicate by ELISAs. **P<0.01 and *** P<0.001. 
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Figure 4: Inflammatory effects of LDL-lipids are removed by statin intervention in 
hypercholesterolaemic patients.  
LDL-lipids (4ђg) from normolipidemic (n=10) and statin-naïve hypercholesterolaemic subject plasmas 
(n=10) pre- and post-statin intervention were investigated for effects on HMVEC barrier function in 
duplicate (A); distribution of tight junction protein ZO-1 in duplicate (B and C); intracellular GSH 
concentration by GSH glo in duplicate (D); secreted IL-6 by ELISA in duplicate (E); and TNF-ɲ by ELISA 
in duplicate (F). *P<0.05, ** P<0.01, ***P<0.001. 
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Figure 5: LDL-lipids are more oxidised and inflammatory in AD (n=10) and AD-Plus patients (n=10) 
compared to controls (n=10). Plasma 8-isoprostane F2ɲ was determined for each plasma in 
triplicate (A). LDL-lipids (4ђg) from patients with AD and AD-Plus were investigated for effects on 
microvascular endothelial barrier function (B) and intracellular GSH concentration by GSH glo assay 
(C) in duplicate for each plasma. Secreted IL-6 (D) levels were measured by IL-6 ELISA in duplicate for 
each plasma.  NS: not significant *P<0.05, **P<0.01 and *** P<0.001. 
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